🚀 VC round data is live in beta, check it out!
NeoGenomics Valuation Multiples
Discover revenue and EBITDA valuation multiples for NeoGenomics and similar public comparables like BioLife Solutions, Azenta, Clinica Baviera, Daan Gene and more.
NeoGenomics Overview
About NeoGenomics
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Founded
1998
HQ
Employees
2.5K
Website
Financials (LTM)
EV
$1B
NeoGenomics Financials
NeoGenomics reported last 12-month revenue of $748M and EBITDA of $47M.
In the same LTM period, NeoGenomics generated $330M in gross profit, $47M in EBITDA, and had net loss of ($94M).
Revenue (LTM)
NeoGenomics P&L
In the most recent fiscal year, NeoGenomics reported revenue of $727M and EBITDA of $43M.
NeoGenomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $748M | XXX | $727M | XXX | XXX | XXX |
| Gross Profit | $330M | XXX | $314M | XXX | XXX | XXX |
| Gross Margin | 44% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $47M | XXX | $43M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| EBIT Margin | (13%) | XXX | (12%) | XXX | XXX | XXX |
| Net Profit | ($94M) | XXX | ($108M) | XXX | XXX | XXX |
| Net Margin | (13%) | XXX | (15%) | XXX | XXX | XXX |
| Net Debt | — | — | $182M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
NeoGenomics Stock Performance
NeoGenomics has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
NeoGenomics' stock price is $8.35.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.0% | XXX | XXX | XXX | $-0.83 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNeoGenomics Valuation Multiples
NeoGenomics trades at 1.8x EV/Revenue multiple, and 28.4x EV/EBITDA.
EV / Revenue (LTM)
NeoGenomics Financial Valuation Multiples
As of April 20, 2026, NeoGenomics has market cap of $1B and EV of $1B.
Equity research analysts estimate NeoGenomics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NeoGenomics has a P/E ratio of (11.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 28.4x | XXX | 30.8x | XXX | XXX | XXX |
| EV/EBIT | (13.3x) | XXX | (15.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | 4.3x | XXX | XXX | XXX |
| P/E | (11.6x) | XXX | (10.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (61.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NeoGenomics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
NeoGenomics Margins & Growth Rates
NeoGenomics' revenue in the last 12 month grew by 10%.
NeoGenomics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
NeoGenomics' rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NeoGenomics' rule of X is 31% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
NeoGenomics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 32% | XXX | 29% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 31% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 13% | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 37% | XXX | 38% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
NeoGenomics Public Comps
See public comps and valuation multiples for other Laboratory Services and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| NeoGenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| BioLife Solutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Azenta | XXX | XXX | XXX | XXX | XXX | XXX |
| Clinica Baviera | XXX | XXX | XXX | XXX | XXX | XXX |
| Daan Gene | XXX | XXX | XXX | XXX | XXX | XXX |
| Guangzhou Wondfo Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NeoGenomics M&A Activity
NeoGenomics acquired XXX companies to date.
Last acquisition by NeoGenomics was on XXXXXXXX, XXXXX. NeoGenomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by NeoGenomics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNeoGenomics Investment Activity
NeoGenomics invested in XXX companies to date.
NeoGenomics made its latest investment on XXXXXXXX, XXXXX. NeoGenomics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by NeoGenomics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NeoGenomics
| When was NeoGenomics founded? | NeoGenomics was founded in 1998. |
| Where is NeoGenomics headquartered? | NeoGenomics is headquartered in United States. |
| How many employees does NeoGenomics have? | As of today, NeoGenomics has over 2K employees. |
| Who is the CEO of NeoGenomics? | NeoGenomics' CEO is Anthony P. Zook. |
| Is NeoGenomics publicly listed? | Yes, NeoGenomics is a public company listed on Nasdaq. |
| What is the stock symbol of NeoGenomics? | NeoGenomics trades under NEO ticker. |
| When did NeoGenomics go public? | NeoGenomics went public in 1996. |
| Who are competitors of NeoGenomics? | NeoGenomics main competitors are BioLife Solutions, Azenta, Clinica Baviera, Daan Gene. |
| What is the current market cap of NeoGenomics? | NeoGenomics' current market cap is $1B. |
| What is the current revenue of NeoGenomics? | NeoGenomics' last 12 months revenue is $748M. |
| What is the current revenue growth of NeoGenomics? | NeoGenomics revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of NeoGenomics? | Current revenue multiple of NeoGenomics is 1.8x. |
| Is NeoGenomics profitable? | Yes, NeoGenomics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of NeoGenomics? | NeoGenomics' last 12 months EBITDA is $47M. |
| What is NeoGenomics' EBITDA margin? | NeoGenomics' last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of NeoGenomics? | Current EBITDA multiple of NeoGenomics is 28.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.